Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients

Nephrology Dialysis Transplantation

Volumn 30, Issue 1, 2015, Pages 84-91

  Isoyama, Naohito ^a,b   Leurs, Paul ^a,c   Qureshi, Abdul Rashid ^a   Bruchfeld, Annette ^a   Anderstam, Björn ^a   Heimburger, Olof ^a   Bárány, Peter ^a   Stenvinkel, Peter ^a   Lindholm, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b YAMAGUCHI UNIVERSITY   (Japan)

^c Admiraal de Ruyter Hospital   (Netherlands)

Author keywords

cardiovascular disease; end stage renal disease; inflammation; mortality; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; PROTEIN S 100; SERUM ALBUMIN; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR; S100A12 PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL STATUS; PERITONEAL DIALYSIS; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; AGED; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; INFLAMMATION; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SURVIVAL RATE;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; S100 PROTEINS; SURVIVAL RATE;

EID: 84922475220     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu259     Document Type: Article

References (41)

1. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-Analysis. Lancet 2012; 380: 1662-1673
2. Park SH, Stenvinkel P, Lindholm B. Cardiovascular biomarkers in chronic kidney disease. J Ren Nutr 2012; 22: 120-127
3. Stenvinkel P, Carrero J, Axelsson J et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521
4. Elewa U, Sanchez-Niño MD, Martin-Cleary C et al. Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled. Int Urol Nephrol 2012; 44: 1731-1744
5. Xu H, Watanabe M, Qureshi A et al. Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. Perit Dial Int 2014; [Epub ahead of print]
6. Leurs P, Lindholm B. The AGE-RAGE pathway and its relation to cardiovascular disease in patients with chronic kidney disease. Arch Med Res 2013; 44: 601-610
7. Park S, Yoon SJ, Tae HJ et al. RAGE and cardiovascular disease. Front Biosci 2011; 16: 486-497
8. Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol 2013; 94: 55-68
9. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-443
10. Selvin E, Halushka MK, Rawlings AM et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013; 62: 2116-2121
11. Mori Y, Kosaki A, Kishimoto N et al. Increased plasma S100A12 (ENRAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009; 29: 18-24
12. Yang Z, Yan WX, Cai H et al. S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity. J Allergy Clin Immunol 2007; 119: 106-114
13. Mahajan N, Malik N, Bahl A et al. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 2009; 207: 597-602
14. Schmidt AM, Yan SD, Yan SF et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955
15. Bucciarelli LG,Wendt T, QuWet al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-2835
16. Schmidt AM, Yan SD, Brett J et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993; 91: 2155-2168
17. Koyama H, Shoji T, Yokoyama H et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 2587-2593
18. Basta G, Sironi AM, Lazzerini G et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006; 91: 4628-4634
19. Peiskerová M, Kalousová M, Danzig V et al. Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease-A prospective observational study. BMC Nephrol 2013; 14: 142
20. Zakiyanov O, Kalousová M, Kříha V et al. Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease. Kidney Blood Press Res 2011; 34: 457-464
21. Kalousová M, Hodková M, Kazderová M et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47: 406-411
22. Gohda T, Tanimoto M, Moon JY et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 2008; 81: 196-201
23. Koyama H, Shoji T, Fukumoto S et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 2007; 27: 147-153
24. Kalousová M, Kuběna AA, Benáková H et al. EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding protein) and mortality of long-term hemodialysis patients: a prospective observational cohort study. Clin Biochem 2012; 45: 556-560
25. Nakashima A, Carrero JJ, Qureshi AR et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 2213-2219
26. Shiotsu Y, Mori Y, Nishimura M et al. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 718-723
27. Kim JK, Park S, Lee MJ et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012; 220: 208-214
28. Uchiyama-Tanaka Y, Mori Y, Kosaki A et al. Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease. Ther Apher Dial 2008; 12: 28-32
29. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911
30. Qureshi AR, Alvestrand A, Danielsson A et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998; 53: 773-782
31. Fouque D, Kalantar-Zadeh K, Kopple J et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73: 391-398
32. Carrero JJ, Stenvinkel P, Cuppari L et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr 2013; 23: 77-90
33. Bruchfeld A, Qureshi A, Lindholm B et al. High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 2008; 14: 109-115
34. Foell D, Ichida F, Vogl T et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 2003; 361: 1270-1272
35. Kallinich T,Wittkowski H, Keitzer R et al. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis 2010; 69: 677-682
36. Wittkowski H, Hirono K, Ichida F et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 2007; 56: 4174-4181
37. Foell D, Kane D, Bresnihan B et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 1383-1389
38. Komatsuda A, Ohtani H, Wakui H et al. Increased serum levels of S100A12 in patients with MPO-ANCA-Associated glomerulonephritis. Clin Nephrol 2006; 66: 315-321
39. Mahajan N, Bahl A, Dhawan V. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol 2010; 142: 273-278
40. Hara M, Ando M, Morito T et al. S100A12 gene expression is increased in peripheral leukocytes in chronic kidney disease stage 4-5 patients with cardiovascular disease. Nephron Clin Pract 2013; 123: 202-208
41. Franke S, Mller A, Sommer M et al. Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol 2003; 59: 88-97